कंडीशन, दवा या प्रायोजक द्वारा ClinicalTrials.gov अध्ययनों की खोज करें और स्थिति, चरण, स्थान, तिथियों और नामांकन को साफ JSON में प्राप्त करें
पोस्टमैन में चलाएँ
{
"tool": "clinical-trials",
"count": 20,
"results": [
{
"query": "semaglutide",
"nctId": "NCT07295223",
"title": "Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)",
"officialTitle": "GLP-1 and Antidiabetic SGLT2 Agents for Myocardial Infarction and Ultrasensitive Inflammatory Surveillance: An Open-Label Pilot Study",
"status": "COMPLETED",
"phases": [
"PHASE3"
],
"studyType": "INTERVENTIONAL",
"conditions": [
"Acute Myocardial Infarction With ST Elevation"
],
"interventions": [
"DRUG: Dapagliflozin 10 MG Oral Tablet",
"DRUG: Semaglutide (Rybelsus®)"
],
"sponsor": "Instituto Mexicano del Seguro Social",
"sponsorClass": "OTHER_GOV",
"enrollment": 44,
"startDate": "2025-12-30",
"primaryCompletionDate": "2026-10-30",
"lastUpdated": "2026-11-04",
"hasResults": false,
"locationCount": 1,
"countries": [
"Mexico"
],
"sampleLocations": [
"Hospital de Especialidades No.1, Centro Médico Nacional del Bajío, León, Guanajuato, Mexico"
],
"briefSummary": "The primary risk factor for coronary artery disease is atherosclerosis, with inflammation playing a crucial role in the development and progression of this condition. It has now been proven that inflammation is key in the development of complications after an acute myocardial infarction. These complications can be immediate and mechanical, such as ventricular wall rupture and ventricular arrhythmia, or long-term, presenting as major cardiovascular events like heart failure.\n\nDuring acute myocardial infarction (AMI), circulating high-sensitivity CRP levels increase approximately 6 hours after the onset of ischemia. CRP levels measured between 24 and 72 hours after symptom onset are a significant prognostic marker for one-year outcomes. Higher high-sensitivity CRP levels at the time of AMI are linked to more severe coronary atherosclerotic lesions seen on angiography and lower LVEF one month after the event. A serum high-sensitivity CRP concentration greater than 10 mg/L after an AMI indicates inflammation, reflecting myocardial necrosis, plaque rupture, and acute thrombosis. In patients with AMI, persistent or increasing CRP levels are strongly associated with a higher risk of all-cause and non-cardiovascular death, especially when inflammation (CRP \\> 2.0 mg/L) continues for a year.\n\nAside from reperfusion therapy, very few pharmacological approaches have been used to reduce inflammation after AMI. One such approach was the use of colchicine in the COVERT-MI randomized, doubl",
"url": "https://clinicaltrials.gov/study/NCT07295223"
},
{
"query": "semaglutide",
"nctId": "NCT07772960",
"title": "Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes",
"officialTitle": "Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes",
"status": "RECRUITING",
"phases": [
"PHASE1"
],
"studyType": "INTERVENTIONAL",
"conditions": [
"Alcohol Use Disorder (AUD)",
"Obesity (BMI Equal to or >30)"
],
"interventions": [
"OTHER: Placebo",
"DRUG: Semaglutide 1.0 mg",
"DRUG: Semaglutide 2.0 mg"
],
"sponsor": "Yale University",
"sponsorClass": "OTHER",
"enrollment": 90,
"startDate": "2026-10-01",
"primaryCompletionDate": "2031-10-31",
"lastUpdated": "2026-11-04",
"hasResults": false,
"locationCount": 2,
"countries": [
"United States"
],
"sampleLocations": [
"Yale Stress Center, New Haven, Connecticut, United States",
"Yale Stress Center, New Haven, Connecticut, United States"
],
"briefSummary": "This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.",
"url": "https://clinicaltrials.gov/study/NCT07772960"
},
{
"query": "semaglutide",
"nctId": "NCT06975111",
"title": "Focusing on the Menopausal Transition to Improve Mid-Life Women's Health",
"officialTitle": "Focusing on the Menopausal Transition to Improve Mid-Life Women's Health",
"status": "RECRUITING",
"phases": [
"PHASE2",
"PHASE3"
],
"studyType": "INTERVENTIONAL",
"conditions": [
"Menopause",
"Menopause Hot Flashes",
"Menopause Related Conditions",
"Cardiovascular"
],
"interventions": [
"DRUG: Metformin",
"DRUG: semaglutide",
"DRUG: Anti-hypertensives",
"DRUG: Lipid Lowering Medication",
"BEHAVIORAL: Life style intervention",
"DRUG: Fezolinetant",
"DRUG: Hormonal therapy"
],
"sponsor": "University of Colorado, Denver",
"sponsorClass": "OTHER",
"enrollment": 200,
"startDate": "2026-03-01",
"primaryCompletionDate": "2029-10-31",
"lastUpdated": "2026-11-04",
"hasResults": false,
"locationCount": 3,
"countries": [
"United States"
],
"sampleLocations": [
"University of Colorado-School of Medicine, Aurora, Colorado, United States",
"University of North Carolina, School of Medicine, Chapel Hill, North Carolina, United States",
"Virginia Commonwealth University, Richmond, Virginia, United States"
],
"briefSummary": "What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.",
"url": "https://clinicaltrials.gov/study/NCT06975111"
},
{
"query": "semaglutide",
"nctId": "NCT06897475",
"title": "A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide",
"officialTitle": "A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal",
"status": "RECRUITING",
"phases": [
"PHASE2"
],
"studyType": "INTERVENTIONAL",
"conditions": [
"Type 2 Diabetes"
],
"interventions": [
"DRUG: LY3457263",
"DRUG: Placebo"
],
"sponsor": "Eli Lilly and Company",
"sponsorClass": "INDUSTRY",
"enrollment": 200,
"startDate": "2025-03-28",
"primaryCompletionDate": "2027-05",
"lastUpdated": "2026-11-04",
"hasResults": false,
"locationCount": 60,
"countries": [
"United States",
"Canada",
"Germany",
"Poland",
"Puerto Rico",
"United Kingdom"
],
"sampleLocations": [
"Helios Clinical Research - Phoenix, Phoenix, Arizona, United States",
"Wolverine Clinical Trials, Santa Ana, California, United States",
"Renstar Medical Research, Ocala, Florida, United States",
"Oviedo Medical Research, Oviedo, Florida, United States",
"Balanced Life Health Care Solutions/SKYCRNG, Lawrenceville, Georgia, United States"
],
"briefSummary": "The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.",
"url": "https://clinicaltrials.gov/study/NCT06897475"
},
{
"query": "semaglutide",
"nctId": "NCT07832084"
}
],
"_note": "Response truncated for documentation purposes"
}
curl --location --request GET 'https://zylalabs.com/api/14726/clinical+trials+search+api/38085/clinical+trials+search?items=semaglutide' --header 'Authorization: Bearer YOUR_API_KEY'
साइन अप करने के बाद, प्रत्येक डेवलपर को एक पर्सनल API एक्सेस की असाइन की जाती है, जो अक्षरों और अंकों का एक यूनिक संयोजन होता है, जिसका उपयोग हमारे API एंडपॉइंट तक पहुंचने के लिए किया जाता है। प्रमाणीकरण के लिए क्लिनिकल ट्रायल्स सर्च API के साथ बस अपने बेयरर टोकन को Authorization हेडर में शामिल करें।
| हेडर | विवरण |
|---|---|
Authorization
|
आवश्यक
होना चाहिए Bearer access_key. जब आप सब्सक्राइब हों तो ऊपर "Your API Access Key" देखें।
|
कोई लंबी अवधि की प्रतिबद्धता नहीं। कभी भी अपग्रेड, डाउनग्रेड या कैंसल करें।
स्थिति, दवा या प्रायोजक द्वारा ClinicalTrials.gov अध्ययन खोजें और स्थिति, चरण, स्थान, तिथियाँ और नामांकन को साफ JSON के रूप में प्राप्त करें
आइटम्स क्वेरी पैरामीटर को 5 मानों (विरामचिह्न से अलग) के साथ भेजें उदाहरण items=semaglutide वैकल्पिक पैरामीटर: कंडीशंस, स्टेटस, स्थान, maxResultsPerQuery
उपकरण, गणना और परिणामों की सरणी के साथ JSON प्रत्येक परिणाम पंक्ति में इस पृष्ठ पर उदाहरण प्रतिक्रिया के समान क्षेत्र होते हैं
एक कॉल एक अनुरोध के रूप में गिनी जाती है भले ही यह एक साथ 5 प्रश्नों के लिए पूछती हो उसी कॉल में अधिक विकल्पों या उच्च सीमा की मांग करना भी एक ही अनुरोध के रूप में गिना जाता है
आधिकारिक सार्वजनिक एपीआई सार्वजनिक वेब पृष्ठ सार्वजनिक फ़ाइलें और डीएनएस अनुरोध समय पर लाइव फ़etch की गईं कोई लॉगइन या कमाई की दीवारें दरकिनार नहीं की गई हैं
अधिकतर कॉल 2 से 15 सेकंड में वापस आते हैं 80 सेकंड से अधिक होने पर आपको HTTP 503 मिलता है जिसमें Retry-After होता है कम आइटम भेजें और पुनः प्रयास करें
वैकल्पिक क्वेरी पैरामीटर: स्थितियाँ, स्थिति, स्थान, प्रति क्वेरी अधिकतम परिणाम। प्रत्येक इस पृष्ठ पर पैरामीटर के अंतर्गत इसके अनुमत मान या सीमा के साथ सूचीबद्ध है। उन सीमाओं के बाहर के मान HTTP 400 लौटाते हैं जिसमें अनुमत सीमा है
JSON एक त्रुटि संदेश के साथ: 400 एक गायब या अवैध पैरामीटर के लिए (अनुमत मानों के साथ) 422 जब कोई वस्तु संसाधित नहीं की जा सकती (प्रत्येक के लिए एक कारण के साथ) 429 दर सीमा के पार 503 जब व्यस्त या 80 सेकंड से अधिक हो Retry-After के साथ यदि केवल कुछ वस्तुएं विफल होती हैं तो आपको उन वस्तुओं के लिए पंक्तियों के साथ 200 मिलता है जो सफल रही हैं
